Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
Cyient Semiconductors Acquires Majority Stake in Kinetic Technologies to Drive Custom Power IC Leadership for Edge AI and High-Performance Compute Markets
HYDERABAD, India, Dec. 19, 2025 /PRNewswire/ -- Cyient Semiconductors has signed a…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
NETFLIX TO ACQUIRE WARNER BROS. FOLLOWING THE SEPARATION OF DISCOVERY GLOBAL FOR A TOTAL ENTERPRISE VALUE OF $82.7 BILLION (Equity Value of $72.0 Billion)
Transaction Unites Warner Bros.' Iconic Franchises and Storied Libraries with Netflix's Leading Entertainment…
Signing Day Sports Shareholder Letter Details AI/HPC Infrastructure Opportunity with BlockchAIn Digital Infrastructure
SCOTTSDALE, AZ, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc.…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
November 26, 2025 19:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
FP Markets Wins Global Broker of the Year at the Finance Magnates Awards 2025
SYDNEY, Nov. 11, 2025 /PRNewswire/ -- FP Markets has been recognised with three prestigious…
Armada Acquisition Corp. II Announces Ticker Symbol to Change to XRPN on Oct 30, 2025
New ticker aligns with new $1 billion strategy for XRP exposure on…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal…